Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Cross

Showing results (241-250 of 313) with videos related to

Pageof 32
Sort By:
Arthritis and Rheumatism|December 13, 2012
Tumor necrosis factor α- and interleukin-1β-dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1Jianru Wang, Ye Tian, Kate L E Phillips, et al.
Crohn'S & Colitis 360|May 25, 2026
Safety of biologics and Janus kinase inhibitors in inflammatory bowel disease patients with low cardiovascular riskParaj Patel, Omair Iqbal, Divyanshu Mohananey, et al.
Radiology|January 31, 2014
Fluoroscopic balloon dilation of esophageal atresia anastomotic strictures in children and young adults: single-center study of 103 consecutive patients from 1999 to 2011Mandela Thyoka, Alex Barnacle, Samantha Chippington, et al.
Journal of Clinical Medicine|October 1, 2020
Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel DiseaseByron P Vaughn, Andres J Yarur, Elliot Graziano, et al.
Arthritis Research & Therapy|December 12, 2013
The cytokine and chemokine expression profile of nucleus pulposus cells: implications for degeneration and regeneration of the intervertebral discKate L E Phillips, Neil Chiverton, Anthony L R Michael, et al.
Journal of Crohn'S & Colitis|December 4, 2025
Efficacy and safety of risankizumab in patients with moderately to severely active Crohn's disease: interim results from the SEQUENCE open-label extension studyLaurent Peyrin-Biroulet, Raja Atreya, Silvio Danese, et al.
The American Journal of Gastroenterology|January 29, 2025
Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical ProgramAndres J Yarur, Millie D Long, Joana Torres, et al.
Inflammatory Bowel Diseases|December 13, 2024
Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical ProgramAndres J Yarur, Michael V Chiorean, Jessica R Allegretti, et al.
The American Journal of Gastroenterology|November 17, 2023
Changes in Therapy Are Not Associated With Increased Remission in Patients With Crohn's Disease of the PouchMaia Kayal, Parakkal Deepak, Poonam Beniwal-Patel, et al.
Gastro Hep Advances|August 12, 2024
Poor Patient-Reported Outcomes and Impaired Work Productivity in Patients With Inflammatory Bowel Disease in RemissionRaymond K Cross, Jenny S Sauk, Joe Zhuo, et al.
Pageof 32

Showing results (241-250 of 313) with videos related to

Sort By:
Pageof 32
Arthritis and Rheumatism|December 13, 2012
Tumor necrosis factor α- and interleukin-1β-dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1Jianru Wang, Ye Tian, Kate L E Phillips, et al.
Crohn'S & Colitis 360|May 25, 2026
Safety of biologics and Janus kinase inhibitors in inflammatory bowel disease patients with low cardiovascular riskParaj Patel, Omair Iqbal, Divyanshu Mohananey, et al.
Radiology|January 31, 2014
Fluoroscopic balloon dilation of esophageal atresia anastomotic strictures in children and young adults: single-center study of 103 consecutive patients from 1999 to 2011Mandela Thyoka, Alex Barnacle, Samantha Chippington, et al.
Journal of Clinical Medicine|October 1, 2020
Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel DiseaseByron P Vaughn, Andres J Yarur, Elliot Graziano, et al.
Arthritis Research & Therapy|December 12, 2013
The cytokine and chemokine expression profile of nucleus pulposus cells: implications for degeneration and regeneration of the intervertebral discKate L E Phillips, Neil Chiverton, Anthony L R Michael, et al.
Journal of Crohn'S & Colitis|December 4, 2025
Efficacy and safety of risankizumab in patients with moderately to severely active Crohn's disease: interim results from the SEQUENCE open-label extension studyLaurent Peyrin-Biroulet, Raja Atreya, Silvio Danese, et al.
The American Journal of Gastroenterology|January 29, 2025
Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical ProgramAndres J Yarur, Millie D Long, Joana Torres, et al.
Inflammatory Bowel Diseases|December 13, 2024
Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical ProgramAndres J Yarur, Michael V Chiorean, Jessica R Allegretti, et al.
The American Journal of Gastroenterology|November 17, 2023
Changes in Therapy Are Not Associated With Increased Remission in Patients With Crohn's Disease of the PouchMaia Kayal, Parakkal Deepak, Poonam Beniwal-Patel, et al.
Gastro Hep Advances|August 12, 2024
Poor Patient-Reported Outcomes and Impaired Work Productivity in Patients With Inflammatory Bowel Disease in RemissionRaymond K Cross, Jenny S Sauk, Joe Zhuo, et al.
Pageof 32